AbbVie: Urinary Bladder, Overactive trials

The registry lists 30 Urinary Bladder, Overactive studies with AbbVie as lead sponsor. 0 are open to participants now and 22 have results posted.

Phase 2 5Phase 3 10Phase 4 9No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary IncontinenceCompletedNCT03320850Phase 2Results posted
• Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary IncontinenceCompletedNCT03052764Phase 4Results posted
• OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)TerminatedNCT02097121Phase 3Results posted
• OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive BladderCompletedNCT01945489Phase 4Results posted
• A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary IncontinenceCompletedNCT01767519Phase 3Results posted
• Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic BladderCompletedNCT01192568Phase 4Results posted
• Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) TrialCompletedNCT01178827Phase 4Results posted
• Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary IncontinenceCompletedNCT01157377Phase 2Results posted
• Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) DailyCompletedNCT01089751Phase 4Results posted
• Trospium Chloride XR in Obese Female Patients With Overactive BladderCompletedNCT00932022Phase 4Results posted
• Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinenceCompletedNCT00915525Phase 3Results posted
• Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinenceCompletedNCT00910845Phase 3Results posted
• Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinenceCompletedNCT00910520Phase 3Results posted
• A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple SclerosisCompletedNCT00876447Phase 3Results posted
• Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) TrialCompletedNCT00863551Phase 4Results posted
• A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor OveractivityTerminatedNCT00712322Phase 2Results posted
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderTerminatedNCT00575016Phase 2Results posted
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderCompletedNCT00461292Phase 3Results posted
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderTerminatedNCT00439140Phase 3Results posted
• A Comparison of a New Drug to Treat Overactive Bladder vs. PlaceboCompletedNCT00350636Phase 3Results posted
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderCompletedNCT00311376Phase 3Results posted
• A Research Study for Patients With Overactive BladderCompletedNCT00168454Phase 2Results posted
• Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)CompletedNCT03043287
• Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive BladderCompletedNCT02673047
• A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean PatientsCompletedNCT02601287Phase 4
• A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in IndiaCompletedNCT02590250
• Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive BladderCompletedNCT02557971
• An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive BladderCompletedNCT02161159
• Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in KoreaCompletedNCT02010788
• Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive BladderCompletedNCT00224146Phase 4